Inhibitors of UHRF1 base flipping activity showing cytotoxicity against cancer cells - Archive ouverte HAL Access content directly
Journal Articles Bioorganic Chemistry Year : 2023

Inhibitors of UHRF1 base flipping activity showing cytotoxicity against cancer cells

Abstract

Ubiquitin-like containing PHD and RING finger domain 1 (UHRF1) is a nuclear multi-domain protein overexpressed in numerous human cancer types. We previously disclosed the anthraquinone derivative UM63 that inhibits UHRF1-SRA domain base-flipping activity, although having DNA intercalating properties. Herein, based on the UM63 structure, new UHRF1-SRA inhibitors were identified through a multidisciplinary approach, combining molecular modelling, biophysical assays, molecular and cell biology experiments. We identified AMSA2 and MPB7, that inhibit UHRF1-SRA mediated base flipping at low micromolar concentrations, but do not intercalate into DNA, which is a key advantage over UM63. These molecules prevent UHRF1/DNMT1 interaction at replication forks and decrease the overall DNA methylation in cells. Moreover, both compounds specifically induce cell death in numerous cancer cell lines, displaying marginal effect on non-cancer cells, as they preferentially affect cells with high level of UHRF1. Overall, these two compounds are promising leads for the development of anti-cancer drugs targeting UHRF1.
Fichier principal
Vignette du fichier
Inhibitors of UHRF1 base flipping revised 2 final.pdf (1.19 Mo) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-04238876 , version 1 (12-10-2023)

Identifiers

Cite

Stefano Ciaco, Viola Mazzoleni, Aqib Javed, Sylvia Eiler, Marc Ruff, et al.. Inhibitors of UHRF1 base flipping activity showing cytotoxicity against cancer cells. Bioorganic Chemistry, 2023, 137, pp.106616. ⟨10.1016/j.bioorg.2023.106616⟩. ⟨hal-04238876⟩
12 View
26 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More